Bard Buys Genyx For Urethral Bulking Agent Following FDA Sign-Off
This article was originally published in The Gray Sheet
Executive Summary
Bard's $60 mil. purchase of Genyx Medical comes less than a month after PMA approval of Genyx's Uryx injectable bulking agent for stress urinary incontinence
You may also be interested in...
Bard Discontinues Tegress Incontinence Product Due To Postmarket Expense
Bard will halt sales of its urinary incontinence bulking agent Tegress while continuing to offer its Contigen collagen-based device, citing excessive costs associated with Tegress' postmarket requirements
Bard Discontinues Tegress Incontinence Product Due To Postmarket Expense
Bard will halt sales of its urinary incontinence bulking agent Tegress while continuing to offer its Contigen collagen-based device, citing excessive costs associated with Tegress' postmarket requirements
New Bulking Agent To Be Marketed By “Major” Urology Firm – BioForm
BioForm Medical is completing a deal with a "major urology player" to market and distribute its new female stress urinary incontinence (SUI) therapy